ACTRN12621001375842已完成1 期
Investigating the impact of of Psilocybin and guided meditation on brain connectivity in healthy adults
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Healthy adults aged between 18-55. No MRI contraindications. Willing to be abstinent from illicit or extra-medical drug and alcohol use for at least 2 days prior to psilocybin dosing. Able to swallow pills.
- •Proficient in English, such that their literacy and comprehension is sufficient for understanding the consent form and study questionnaires, as evaluated by study staff obtaining consent. (Funds available for this research would preclude access to translators to enable non-English speaker participation.) Limited previous exposure to psychedelics and meditation practices.
排除标准
- •Current or previously diagnosed psychiatric disorder (as determined by the SCID). Current or past history within the last 5 years of meeting DSM-5 criteria for alcohol or drug dependence (excluding caffeine and nicotine), as determined by clinical interview and use of screening measures. Immediate family member with a diagnosed psychotic disorder (Schizophrenia spectrum, Disorder or Bipolar I or II Disorder). History of suicide attempts. No use of any hallucinogen or psychedelic (including psilocybin, MDMA, LSD, mescaline, DMT, and other similar hallucinogenic compounds) within the past 6 months. Taking a contraindicated medication (SSRIs, SNRIs, MAOIs) at the time of recruitment. Currently use of any of the following potent metabolic inducers or inhibitors: Inducers - Rifamycin (rifampin, rifabutin, rifapentine), anticonvulsants (carbamazepine, phenytoin, phenobarbital), nevirapine, efavirenz, paclitaxol, St John's Wort; Inhibitors - all HIV protease inhibitors, itraconazole, ketoconazole, erythromycin, clarithromycin, troleandomycin. Known conditions putting participants at risk for hypercalcaemia, Cushing's syndrome, hypoglycaemia, syndrome of inappropriate antidiuretic hormone secretion, or carcinoid syndrome. People with a medical requirement that they receive any of the following drugs with low therapeutic index within 12 hours after receiving psilocybin: ergot alkaloids, pimozide, midazolam, triazolam, lovastatin, simvastatin, fentanyl. A diagnosis of epilepsy or previous seizures. Hepatic dysfunction. Renal insufficiency (creatinine clearance < 40 mL/min using the Cockraft and Gault equation). Body weight < 48kg. Taking long-acting opioid pain medications (e.g. oxycodone sustained release, morphine sustained release -- which are usually taken at 12-hour intervals) unless last dose occurred at least 6 hours before psilocybin administration; such medication will not be taken again until at least 6 hours after psilocybin administration. Cardiovascular conditions: uncontrolled hypertension, (Systolic >140 and diastolic >90) angina, a clinically significant ECG abnormality (e.g. atrial fibrillation, arrhythmia, prolongation of QT/QTc interval), TIA in the last 6 months, stroke or cerebrovascular disease, peripheral or pulmonary vascular disease (no active claudication). Medically significant condition rendering unsuitability for the study (e.g., diabetes, epilepsy, severe cardiovascular disease, hepatic or renal failure etc). Treatment in another clinical trial involving an investigational product. Positive pregnancy test at screening or during the study. Are unable to give adequate informed consent. Allergy to gelatine or lactose.
研究者
相似试验
尚未招募
2 期
Feasibility study testing the protocol of single dose of psilocybin given to people who have had little improvements with brief psychological interventioMental Health - AnxietyMental Health - DepressionDepressionAnxietyACTRN12624000816550niversity of Otago30
招募中
Unknown
Psilocybin administration for treatment-resistant depressiodepressionD061218Treatment-resistant depressionJPRN-jRCTs031230351chida Hiroyuki12
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873EUCTR2017-003288-36-CZCOMPASS Pathfinder, Limited216
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioEUCTR2017-003288-36-PTCOMPASS Pathfinder Limited216
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873EUCTR2017-003288-36-DECOMPASS Pathfinder, Limited398